Targeting autophagy reverses de novo resistance in homologous recombination repair proficient breast cancers to PARP inhibition
Open Access
- 21 January 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 124 (7), 1260-1274
- https://doi.org/10.1038/s41416-020-01238-0
Abstract
Background Poly(ADP-ribose) polymerase inhibitors (PARPi) target tumours defective in homologous recombination (HR). Most BRCA-wild-type (WT) HR-proficient breast cancers are intrinsically resistant to PARP inhibitors, e.g., talazoparib. We evaluated the role of autophagy in this de novo resistance and determined the underlying mechanism to overcome this. Methods Autophagosome formation and autophagic flux were assessed by evaluating endogenous LC3-II levels and ectopic expression of EGFP-LC3 and mRFP-EGFP-LC3 in breast cancer cells. Autophagy-defective cells were generated by genetic depletion of BECN1, ATG5, p62/SQSTM1 and LAMP1 by using CRISPR-Cas9 double nickase system. The response of PARPi was evaluated in autophagy-proficient and -defective breast cancer cells and in xenograft SCID-mice model. Results Pro-survival autophagy was significantly enhanced upon talazoparib treatment in BRCA-WT breast cancer cell lines. Autophagy-deficient cells were hypersensitive to talazoparib. Targeting autophagy synergistically enhanced the therapeutic efficacy of talazoparib in BRCA1-WT breast cancer cells in vitro and in vivo xenograft tumour mouse model. Mechanistically, autophagy inhibition by chloroquine promoted deleterious NHEJ mediated DSB-repair, leading to extensive genomic instability and mitotic catastrophe. Conclusions Autophagy confers de novo resistance to PARP inhibitor, talazoparib. Autophagy inhibition improves the therapeutic outcome of PARPi treatment in preclinical mice model, bearing HR-proficient breast tumours, warranting its usage in the clinical settings.Funding Information
- Department of Atomic Energy, Government of India (XII Plan, BRNS fund, XII Plan fund)
This publication has 53 references indexed in Scilit:
- Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatmentCell Death & Disease, 2013
- BRCA1-associated exclusion of 53BP1 from DNA damage sites underlies temporal control of DNA repairJournal of Cell Science, 2012
- Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cellsProceedings of the National Academy of Sciences of the United States of America, 2011
- Autophagy in mammalian development and differentiationNature, 2010
- Methods in Mammalian Autophagy ResearchCell, 2010
- Regulation Mechanisms and Signaling Pathways of AutophagyAnnual Review of Genetics, 2009
- Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesisGenes & Development, 2007
- Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature, 2005
- Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymeraseNature, 2005
- Endocytosis and the recycling of plasma membrane.The Journal of cell biology, 1983